ARVINAS, INC.
Tremor tracks 4 of its cancer trials.
Company-wide warning signs
These add points to every one of this company's trials.
- 5 insiders sold shares within a monthSince May 21, 2026+1.4
Trials
- ARVNArvinas Inc.11Calm
Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer
FinishedPhase 1/2248 patientsMain results: Apr 29, 2024 - ARVNArvinas Inc.1Calm
A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
Signing up patientsPhase 1/2499 patientsMain results: Mar 31, 2031 - ARVNArvinas Inc.1Calm
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
Running, no new patientsPhase 1/276 patientsMain results: Nov 30, 2026 - ARVNArvinas Inc.1Calm
A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery
FinishedPhase 2152 patientsMain results: Jul 13, 2024
Key executives leaving
From the last 12 months of the company's SEC reports.
Insider trades (last 6 months)
“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.
8 sales (6 not pre-planned) · 0 purchases
- Saik AndrewChief Financial Officer · Jun 24, 2026Sold 5,696 sharesabout $46 thousand · pre-planned
- Cacace Angela MChief Scientific Officer · Jun 17, 2026Sold 2,576 sharesabout $20 thousand · pre-planned
- Teel RandyPresident and CEO · May 21, 2026Sold 2,209 sharesabout $20 thousand · not pre-planned
- Saik AndrewChief Financial Officer · May 11, 2026Sold 11,139 sharesabout $111 thousand · not pre-planned
- Loomis David KVP, Chief Accounting Officer · May 11, 2026Sold 1,919 sharesabout $19 thousand · not pre-planned
- Cacace Angela MChief Scientific Officer · May 11, 2026
Recent SEC filings
Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.
- Permission to sell new sharesPermission to sell new shares (S-3)Nov 3, 2026
- Quarterly reportQuarterly report (10-Q)Nov 3, 2026
- Shared quarterly results; Shared information with investorsNews report (8-K)Nov 3, 2026
- Quarterly reportQuarterly report (10-Q)Aug 4, 2026
- Shared quarterly resultsNews report (8-K)Aug 4, 2026